<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Clinical Trial Insights</title>
  <style>
    body { font-family: Arial, sans-serif; padding: 2rem; background: #f5f6fa; }
    h1 { color: #2c3e50; }
    h2 { color: #34495e; margin-top: 2rem; border-bottom: 2px solid #0f6db5; padding-bottom: 0.5rem; }
    table { border-collapse: collapse; width: 100%; background: white; box-shadow: 0 2px 8px rgba(0,0,0,0.08); margin-bottom: 2rem; }
    th, td { padding: 0.6rem 0.9rem; text-align: left; border-bottom: 1px solid #e1e4eb; }
    th { background: #0f6db5; color: white; }
    tr:hover { background: #f0f8ff; }
    a { color: #0066cc; text-decoration: none; }
    a:hover { text-decoration: underline; color: #004499; }
    .status-new { background: #d4edda; color: #155724; font-weight: bold; padding: 4px 8px; border-radius: 4px; }
    .status-changed { background: #fff3cd; color: #856404; font-weight: bold; padding: 4px 8px; border-radius: 4px; }
    .status-existing { color: #6c757d; padding: 4px 8px; }
    .pfizer-section { background: #fff9e6; padding: 1rem; border-radius: 8px; margin-top: 2rem; }
  </style>
</head>
<body>
  <h1>Lab Demand Signals</h1>

  <h2>Academic & Small Biotech Trials</h2>
  <table>
    <tr>
      <th>Principal investigator</th>
      <th>Email</th>
      <th>Phone</th>
      <th>Institution</th>
      <th>Product</th>
      <th>Demand signal</th>
      <th>Status</th>
      <th>Demand reason</th>
      <th>Trial (NCT Link)</th>
      <th>Detected at</th>
    </tr>
    <tr><td>Christine Chung</td><td><a href="mailto:kaleigh.tanner@moffitt.org">kaleigh.tanner@moffitt.org</a></td><td>813-745-2160</td><td>Moffitt Cancer Center</td><td>Monoclonal Antibodies</td><td>High</td><td><span class="status-existing">existing</span></td><td>Cetuximab is given intravenously with a 400 mg/m2 loading dose on C1D1 followed by 250 mg/m2 weekly doses on C1D8, C1D15, and C2D1.</td><td><a href="https://clinicaltrials.gov/study/NCT06855212" target="_blank" title="A Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for Head and Neck Squamous Cell Carcinoma">A Phase II Study of Neoadjuvant Cetuximab and Cemi...<br><small style="color: #0066cc;">NCT06855212</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Christine Chung</td><td><a href="mailto:kaleigh.tanner@moffitt.org">kaleigh.tanner@moffitt.org</a></td><td>813-745-2160</td><td>Moffitt Cancer Center</td><td>IV Infusion Sets</td><td>Medium</td><td><span class="status-new">NEW</span></td><td>Required for intravenous administration of cemiplimab and cetuximab during neoadjuvant therapy.</td><td><a href="https://clinicaltrials.gov/study/NCT06855212" target="_blank" title="A Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for Head and Neck Squamous Cell Carcinoma">A Phase II Study of Neoadjuvant Cetuximab and Cemi...<br><small style="color: #0066cc;">NCT06855212</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Christine Chung</td><td><a href="mailto:kaleigh.tanner@moffitt.org">kaleigh.tanner@moffitt.org</a></td><td>813-745-2160</td><td>Moffitt Cancer Center</td><td>Blood Collection Tubes</td><td>Medium</td><td><span class="status-new">NEW</span></td><td>Needed for blood sample collection to monitor patient response and safety during the trial.</td><td><a href="https://clinicaltrials.gov/study/NCT06855212" target="_blank" title="A Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for Head and Neck Squamous Cell Carcinoma">A Phase II Study of Neoadjuvant Cetuximab and Cemi...<br><small style="color: #0066cc;">NCT06855212</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Christine Chung</td><td><a href="mailto:kaleigh.tanner@moffitt.org">kaleigh.tanner@moffitt.org</a></td><td>813-745-2160</td><td>Moffitt Cancer Center</td><td>Formalin Solution</td><td>Medium</td><td><span class="status-new">NEW</span></td><td>Used for fixation of surgical tissue specimens to assess pathologic response.</td><td><a href="https://clinicaltrials.gov/study/NCT06855212" target="_blank" title="A Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for Head and Neck Squamous Cell Carcinoma">A Phase II Study of Neoadjuvant Cetuximab and Cemi...<br><small style="color: #0066cc;">NCT06855212</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Christine Chung</td><td><a href="mailto:kaleigh.tanner@moffitt.org">kaleigh.tanner@moffitt.org</a></td><td>813-745-2160</td><td>Moffitt Cancer Center</td><td>Immunohistochemistry (IHC) Antibodies</td><td>Low</td><td><span class="status-existing">existing</span></td><td>Used for IHC staining to evaluate PD-1 expression in tumor tissue samples.</td><td><a href="https://clinicaltrials.gov/study/NCT06855212" target="_blank" title="A Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for Head and Neck Squamous Cell Carcinoma">A Phase II Study of Neoadjuvant Cetuximab and Cemi...<br><small style="color: #0066cc;">NCT06855212</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Jennifer Gewandter, PhD, MPH</td><td><a href="mailto:rachel_deguzman@urmc.rochester.edu">rachel_deguzman@urmc.rochester.edu</a></td><td>585-275-9361</td><td>University of Rochester</td><td>Blood Collection Tubes</td><td>High</td><td><span class="status-new">NEW</span></td><td>Required for collecting blood samples from participants for potential biomarker or genetic analysis.</td><td><a href="https://clinicaltrials.gov/study/NCT06614322" target="_blank" title="Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.">Sensory Phenotyping to Enhance Neuropathic Pain Dr...<br><small style="color: #0066cc;">NCT06614322</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Jennifer Gewandter, PhD, MPH</td><td><a href="mailto:rachel_deguzman@urmc.rochester.edu">rachel_deguzman@urmc.rochester.edu</a></td><td>585-275-9361</td><td>University of Rochester</td><td>Capsules for Oral Drug Administration</td><td>High</td><td><span class="status-existing">existing</span></td><td>Study drug used in one of the three treatment arms for analgesic effect evaluation.</td><td><a href="https://clinicaltrials.gov/study/NCT06614322" target="_blank" title="Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.">Sensory Phenotyping to Enhance Neuropathic Pain Dr...<br><small style="color: #0066cc;">NCT06614322</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Jennifer Gewandter, PhD, MPH</td><td><a href="mailto:rachel_deguzman@urmc.rochester.edu">rachel_deguzman@urmc.rochester.edu</a></td><td>585-275-9361</td><td>University of Rochester</td><td>Placebo Capsules</td><td>High</td><td><span class="status-new">NEW</span></td><td>Placebo control capsules used in the cross-over trial design.</td><td><a href="https://clinicaltrials.gov/study/NCT06614322" target="_blank" title="Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.">Sensory Phenotyping to Enhance Neuropathic Pain Dr...<br><small style="color: #0066cc;">NCT06614322</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Jennifer Gewandter, PhD, MPH</td><td><a href="mailto:rachel_deguzman@urmc.rochester.edu">rachel_deguzman@urmc.rochester.edu</a></td><td>585-275-9361</td><td>University of Rochester</td><td>Quantitative Sensory Testing (QST) Sensory Stimulus Devices</td><td>Medium</td><td><span class="status-new">NEW</span></td><td>Used to perform quantitative sensory testing exams to classify pain sub-groups.</td><td><a href="https://clinicaltrials.gov/study/NCT06614322" target="_blank" title="Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.">Sensory Phenotyping to Enhance Neuropathic Pain Dr...<br><small style="color: #0066cc;">NCT06614322</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Jennifer Gewandter, PhD, MPH</td><td><a href="mailto:rachel_deguzman@urmc.rochester.edu">rachel_deguzman@urmc.rochester.edu</a></td><td>585-275-9361</td><td>University of Rochester</td><td>Quantitative Sensory Testing (QST) Mechanical Stimulus Devices</td><td>Medium</td><td><span class="status-new">NEW</span></td><td>Used during QST exams to assess mechanical pain thresholds.</td><td><a href="https://clinicaltrials.gov/study/NCT06614322" target="_blank" title="Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.">Sensory Phenotyping to Enhance Neuropathic Pain Dr...<br><small style="color: #0066cc;">NCT06614322</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>H. Lundbeck A/S</td><td><a href="mailto:LundbeckClinicalTrials@Lundbeck.com">LundbeckClinicalTrials@Lundbeck.com</a></td><td>+45 36301311</td><td>N/A</td><td>Cortisol ELISA Kits</td><td>High</td><td><span class="status-new">NEW</span></td><td>Required to measure cortisol levels in plasma and saliva samples to assess the effect of Lu AG13909 on cortisol in Cushing's disease patients.</td><td><a href="https://clinicaltrials.gov/study/NCT06471829" target="_blank" title="A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease">A Phase II, Multi-site, Open-label, Dose-titration...<br><small style="color: #0066cc;">NCT06471829</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>H. Lundbeck A/S</td><td><a href="mailto:LundbeckClinicalTrials@Lundbeck.com">LundbeckClinicalTrials@Lundbeck.com</a></td><td>+45 36301311</td><td>N/A</td><td>Urinary Free Cortisol (UFC) Assay Kits</td><td>High</td><td><span class="status-new">NEW</span></td><td>Used to quantify urinary free cortisol to evaluate UFC complete and partial response endpoints during titration and maintenance periods.</td><td><a href="https://clinicaltrials.gov/study/NCT06471829" target="_blank" title="A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease">A Phase II, Multi-site, Open-label, Dose-titration...<br><small style="color: #0066cc;">NCT06471829</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>H. Lundbeck A/S</td><td><a href="mailto:LundbeckClinicalTrials@Lundbeck.com">LundbeckClinicalTrials@Lundbeck.com</a></td><td>+45 36301311</td><td>N/A</td><td>Anti-Drug Antibody (ADA) Detection Kits</td><td>Medium</td><td><span class="status-new">NEW</span></td><td>Needed to detect anti-drug antibodies against Lu AG13909 to monitor immunogenicity in participants.</td><td><a href="https://clinicaltrials.gov/study/NCT06471829" target="_blank" title="A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease">A Phase II, Multi-site, Open-label, Dose-titration...<br><small style="color: #0066cc;">NCT06471829</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>H. Lundbeck A/S</td><td><a href="mailto:LundbeckClinicalTrials@Lundbeck.com">LundbeckClinicalTrials@Lundbeck.com</a></td><td>+45 36301311</td><td>N/A</td><td>Pharmacokinetic (PK) Sample Preparation Kits</td><td>Medium</td><td><span class="status-new">NEW</span></td><td>Used for preparation of plasma samples for pharmacokinetic analysis of Lu AG13909 including AUC, Cmax, Tmax, and clearance.</td><td><a href="https://clinicaltrials.gov/study/NCT06471829" target="_blank" title="A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease">A Phase II, Multi-site, Open-label, Dose-titration...<br><small style="color: #0066cc;">NCT06471829</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>H. Lundbeck A/S</td><td><a href="mailto:LundbeckClinicalTrials@Lundbeck.com">LundbeckClinicalTrials@Lundbeck.com</a></td><td>+45 36301311</td><td>N/A</td><td>Saliva Collection Devices</td><td>Low</td><td><span class="status-new">NEW</span></td><td>Required for collection of late night salivary cortisol samples to assess LNSC endpoints.</td><td><a href="https://clinicaltrials.gov/study/NCT06471829" target="_blank" title="A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease">A Phase II, Multi-site, Open-label, Dose-titration...<br><small style="color: #0066cc;">NCT06471829</small></a></td><td>2025-12-24 05:27:47</td></tr>
  </table>

  <div class="pfizer-section">
    <h2>Pfizer Trials (Specialty Products Only)</h2>
    <p><strong>Note:</strong> These are Pfizer-sponsored trials. Only specialty outsourced products are shown.</p>
  </div>
  <table>
    <tr>
      <th>Principal investigator</th>
      <th>Email</th>
      <th>Phone</th>
      <th>Institution</th>
      <th>Product</th>
      <th>Demand signal</th>
      <th>Status</th>
      <th>Demand reason</th>
      <th>Trial (NCT Link)</th>
      <th>Detected at</th>
    </tr>
    <tr><td>Pfizer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>Custom assay development</td><td>High</td><td><span class="status-new">NEW</span></td><td>Required to identify and confirm DDR gene mutations in metastatic castration-sensitive prostate cancer patients for eligibility and stratification.</td><td><a href="https://clinicaltrials.gov/study/NCT04821622" target="_blank" title="TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER">TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ST...<br><small style="color: #0066cc;">NCT04821622</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Pfizer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>Biomarker assay kits (niche/specific)</td><td>High</td><td><span class="status-new">NEW</span></td><td>Used to measure circulating tumor DNA burden at baseline and during study to correlate with clinical outcomes.</td><td><a href="https://clinicaltrials.gov/study/NCT04821622" target="_blank" title="TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER">TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ST...<br><small style="color: #0066cc;">NCT04821622</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Pfizer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>Mechanism-of-action assays</td><td>Medium</td><td><span class="status-new">NEW</span></td><td>Assesses talazoparibâ€™s mechanism of action by measuring PARP enzyme inhibition in patient samples.</td><td><a href="https://clinicaltrials.gov/study/NCT04821622" target="_blank" title="TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER">TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ST...<br><small style="color: #0066cc;">NCT04821622</small></a></td><td>2025-12-24 05:27:47</td></tr>
    <tr><td>Pfizer</td><td>N/A</td><td>N/A</td><td>N/A</td><td>Custom antibodies</td><td>Medium</td><td><span class="status-new">NEW</span></td><td>Used to detect DNA damage response activation in tumor biopsy samples as a pharmacodynamic biomarker.</td><td><a href="https://clinicaltrials.gov/study/NCT04821622" target="_blank" title="TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER">TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ST...<br><small style="color: #0066cc;">NCT04821622</small></a></td><td>2025-12-24 05:27:47</td></tr>
  </table>
</body>
</html>
